Botulinum neurotoxins

Toxicon

Volumn 67, Issue , 2013, Pages 31-36

  Rossetto, O ^a,b   Megighian, A ^a,b   Scorzeto, M ^a,b   Montecucco, C ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b NONE   (Italy)

Author keywords

Botulinum neurotoxins; Botulism; Neuromuscular junction; SNARE proteins

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN C; BOTULINUM TOXIN D; BOTULINUM TOXIN E; SNARE PROTEIN; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN; TETANUS TOXIN; UNCLASSIFIED DRUG;

ANTICONVULSANT ACTIVITY; BOTULISM; CLOSTRIDIUM; DNA SEQUENCE; DRUG EFFICACY; DRUG SPECIFICITY; FLACCID PARALYSIS; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; LD 50; NEUROTOXICITY; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SEIZURE; STRABISMUS;

EID: 84875262150     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2013.01.017     Document Type: Review

References (93)

1. Antonucci F., Rossi C., Gianfranceschi L., Rossetto O., Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J. Neurosci. 2008, 28:3689-3696.
2. Aoki K.R. Future aspects of botulinum neurotoxins. J. Neural Transm. 2008, 115:567-573.
3. Arndt J.W., Jacobson M.J., Abola E.E., Forsyth C.M., Tepp W.H., Marks J.D., Johnson E.A., Stevens R.C. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J. Mol. Biol. 2006, 362:733-742.
4. Arnon S.S., Damus K., Chin J. Infant botulism: epidemiology and relation to sudden infant death syndrome. Epidemiol. Rev. 1981, 3:45-66.
5. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., Tonat K. Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070.
6. Binz T., Rummel A. Cell entry strategy of clostridial neurotoxins. J. Neurochem. 2009, 109:1584-1595.
7. Binz T., Kurazono H., Wille M., Frevert J., Wernars K., Niemann H. The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins. J. Biol. Chem. 1990, 265:9153-9158.
8. Binz T., Blasi J., Yamasaki S., Baumeister A., Link E., Südhof T.C., Jahn R., Niemann H. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J. Biol. Chem. 1994, 269:1617-1620.
9. Binz T., Bade S., Rummel A., Kollewe A., Alves J. Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization. Biochemistry 2002, 41:1717-1723.
10. Blasi J., Chapman E.R., Link E., Binz T., Yamasaki S., De Camilli P., Südhof T., Nieman H., Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993, 365:160-163.
11. Blasi J., Chapman E.R., Yamasaki S., Binz T., Nieman H., Jahn R. Botulinum neurotoxin C blocks neurotransmitter release by means of cleaving HPC-I/syntaxin. EMBO J. 1993, 12:4821-4828.
12. Breidenbach M.A., Brunger A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004, 432:925-929.
13. Brunger A.T., Rummel A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon 2009, 54:550-560.
14. Burgen A.S.V., Dickens F., Zatman L.J. The action of botulinum toxin at the neuro-muscular junction. J. Physiol. (London) 1949, 109:10-24.
15. Caleo M., Schiavo G. Central effects of tetanus and botulinum neurotoxins. Toxicon 2009, 54:593-599.
16. Carli L., Montecucco C., Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 2009, 40:374-380.
17. Chai Q., Arndt J.W., Dong M., Tepp W.H., Johnson E.A., Chapman E.R., Stevens R.C. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 2006, 444:1096-1100.
18. Chertow D.S., Tan E.T., Maslanka S.E., Schulte J., Bresnitz E.A., Weisman R.S., Bernstein J., Marcus S.M., Kumar S., Malecki J., Sobel J., Braden C.R. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006, 296:2476-2479.
19. Chiba A., Kusunoki S., Shimizu T., Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann. Neurol. 1992, 31:677-679.
20. Coffield J.A., Bakry N., Zhang R.D., Carlson J., Gomella L.G., Simpson L.L. In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches. J. Pharmacol. Exp. Ther. 1997, 280:1489-1498.
21. Costantin L., Bozzi Y., Richichi C., Viegi A., Funicello M., Gobbi M., Mennini T., Rossetto O., Montecucco C., Maffei L., Vezzani A., Caleo M. Anti-epileptic effects of botulinum toxin E. J. Neurosci. 2005, 25:1943-1951.
22. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
23. Dong M., Liu H., Tepp W.H., Johnson E.A., Janz R., Chapman E.R. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol. Biol. Cell. 2008, 19:5226-5237.
24. Erbguth F.J. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov. Disord. 2004, 19(Suppl. 8):S2-S6.
25. Fischer A., Montal M. Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10447-10452.
26. Gu S., Rumpel S., Zhou J., Strotmeier J., Bigalke H., Perry K., Shoemaker C.B., Rummel A., Jin R. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 2012, 335:977-981.
27. Hakami R.M., Ruthel G., Stahl A.M., Bavari S. Gaining ground: assays for therapeutics against botulinum neurotoxin. Trends Microbiol. 2010, 18:164-172.
28. Hill K.K., Smith T.J., Helma C.H., Ticknor L.O., Foley B.T., Svensson R.T., Brown J.L., Johnson E.A., Smith L.A., Okinaka R.T., Jackson P.J., Marks J.D. Genetic diversity among botulinum neurotoxin-producing clostridial strains. J. Bacteriol. 2007, 189:818-832.
29. Humeau Y., Doussau F., Grant N.J., Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000, 82:427-446.
30. Jahn R., Scheller R.H. SNAREs - engines for membrane fusion. Nat. Rev. Mol. Cell. Biol. 2006, 7:631-643.
31. Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry 2004, 75:951-957.
32. Jin R., Rummel A., Binz T., Brunger A.T. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 2006, 444:1092-1095.
33. Jin R., Sikorra S., Stegmann C.M., Pich A., Binz T., Brunger A.T. Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity. Biochemistry 2007, 46:10685-10693.
34. Johnson E.A., Montecucco C. Botulism. Handbook of Clinical Neurology 2008, vol. 91 (3rd series):333-368. Elsevier B.V. A.G. Engel (Ed.).
35. Kalb S.R., Baudys J., Rees J.C., Smith T.J., Smith L.A., Helma C.H., Hill K., Kull S., Kirchner S., Dorner M.B., Dorner B.G., Pirkle J.L., Barr J.R. De novo subtype and strain identification of botulinum neurotoxin type B through toxin proteomics. Anal. Bioanal. Chem. 2012, 403:215-226.
36. Kalb S.R., Baudys J., Webb R.P., Wright P., Smith T.J., Smith L.A., Fernandez R., Raphael B.H., Maslanka S.E., Pirkle J.L., Barr J.R. Discovery of a novel enzymatic cleavage site for botulinum neurotoxin F5. FEBS Lett. 2012, 586:109-115.
37. Karalewitz A.P., Kroken A.R., Fu Z., Baldwin M.R., Kim J.J., Barbieri J.T. Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA. Biochemistry 2010, 49:8117-8126.
38. Kroken A.R., Karalewitz A.P., Fu Z., Kim J.J., Barbieri J.T. Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons. J. Biol. Chem. 2011, 286:26828-26837.
39. Kumaran D., Eswaramoorthy S., Furey W., Navaza J., Sax M., Swaminathan S. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J. Mol. Biol. 2009, 386:233-245.
40. Lacy D.B., Stevens R.C. Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol. 1999, 291:1091-1104.
41. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., Stevens R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5:898-902.
42. Luvisetto S., Rossetto O., Montecucco C., Pavone F. Toxicity of botulinum neurotoxins in central nervous system of mice. Toxicon 2003, 41:475-481.
43. Luvisetto S., Marinelli S., Rossetto O., Montecucco C., Pavone F. Central injection of botulinum neurotoxins: behavioural effects in mice. Behav. Pharmacol. 2004, 15:233-240.
44. Mahrhold S., Rummel A., Bigalke H., Davletov B., Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 2006, 580:2011-2014.
45. Montal M. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem. 2010, 79:591-617.
46. Montecucco C. How do tetanus and botulinum toxins bind to neuronal membranes?. Trends Biochem. Sci. 1986, 11:314-317.
47. Montecucco C., Molgó J. Botulinal neurotoxins: revival of an old killer. Curr. Opin. Pharmacol. 2005, 5:274-279.
48. Montecucco C., Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q. Rev. Biophys. 1995, 28:423-472.
49. Montecucco C., Schiavo G., Papini E. Bacterial protein toxins penetrate cells via a four-step mechanism. FEBS Lett. 1994, 346:92-98.
50. Montecucco C., Rossetto O., Schiavo G. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol. 2004, 12:442-446.
51. Montecucco C., Schiavo G., Pantano S. SNARE complexes and neuroexocytosis: how many, how close?. Trends Biochem. Sci. 2005, 30:367-372.
52. Muraro L., Tosatto S., Motterlini L., Rossetto O., Montecucco C. The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane. Biochem. Biophys. Res. Commun. 2009, 380:76-80.
53. Naumann M., So Y., Argoff C.E., Childers M.K., Dykstra D.D., Gronseth G.S., Jabbari B., Kaufmann H.C., Schurch B., Silberstein S.D., Simpson D.M. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1707-1714.
54. Niemann H. Clostridial neurotoxins - proposal of a common nomenclature. Toxicon 1992, 30:223-225.
55. Nishiki T., Kamata Y., Nemoto Y., Omori A., Ito T., Takahashi M., Kozaki S. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J. Biol. Chem. 1994, 269:10498-10503.
56. Peck M.W., Stringer S.C., Carter A.T. Clostridium botulinum in the post-genomic era. Food Microbiol. 2011, 28:183-191.
57. Pellizzari R., Rossetto O., Lozzi L., Giovedì S., Johonson E., Shone C.C., Montecucco C. Structural determinants of the specificity for VAMP/synaptobrevin of tetanus and botulinum B and G neurotoxins. J. Biol. Chem. 1996, 271:20353-20358.
58. Pellizzari R., Mason S., Shone C.C., Montecucco C. The interaction of synaptic vesicle-associated membrane protein/synaptobrevin with botulinum neurotoxins D and F. FEBS Lett. 1997, 409:339-342.
59. Peng L., Tepp W.H., Johnson E.A., Dong M. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 2011, 7:e1002008.
60. Pirazzini M., Rossetto O., Bolognese P., Shone C.C., Montecucco C. Double anchorage to the membrane and intact inter-chain disulfide bond are required for the low pH induced entry of tetanus and botulinum neurotoxins into neurons. Cell. Microbiol. 2011, 13:1731-1743.
61. Pohanka M., Kuca K. Biological warfare agents. Clinical Toxicology 2010, vol. 2:559-578. Birkháuser Verlag, Switzerland. A. Luch (Ed.).
62. Rao K.N., Kumaran D., Binz T., Swaminathan S. Structural analysis of the catalytic domain of tetanus neurotoxin. Toxicon 2005, 45:929-939.
63. Rigoni M., Caccin P., Johnson E.A., Montecucco C., Rossetto O. Site-directed mutagenesis identifies active site residues of the light chain of botulinum neurotoxin type A. Biochem. Biophys. Res. Commun. 2001, 288:1231-1237.
64. Rossetto O., Schiavo G., Montecucco C., Poulain B., Deloye F., Lozzi L., Shone C.C. SNARE motif and neurotoxin recognition. Nature 1994, 372:415-416.
65. Rummel A., Eichner T., Weil T., Karnath T., Gutcaits A., Mahrhold S., Sandhoff K., Proia R.L., Acharya K.R., Bigalke H., Binz T. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:359-364.
66. Rummel A., Hafner K., Mahrhold S., Darashchonak N., Holt M., Jahn R., Beermann S., Karnath T., Bigalke H., Binz T. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J. Neurochem. 2009, 110:1942-1954.
67. Schiavo G., Poulain B., Rossetto O., Benfenati F., Tauc L., Montecucco C. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J. 1992, 11:3577-3583.
68. Schiavo G., Benfenati F., Poulain B., Rossetto O., Polverino de Laureto P., DasGupta B.R., Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by a proteolytic cleavage of synaptobrevin. Nature 1992, 359:832-835.
69. Schiavo G., Rossetto O., Santucci A., DasGupta B.R., Montecucco C. Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 1992, 267:23479-23483.
70. Schiavo G., Rossetto O., Catsicas S., Polverino de Laureto P., DasGupta B.R., Benfenati F., Montecucco C. Identification of the nerve-terminal targets of botulinum neurotoxins serotype A, D and E. J. Biol. Chem. 1993, 268:23784-23787.
71. Schiavo G., Shone C.C., Rossetto O., Alexandre F.C.G., Montecucco C. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J. Biol. Chem. 1993, 268:11516-11519.
72. Schiavo G., Santucci A., DasGupta B.R., Mehta P.P., Jontes J., Benfenati F., Wilson M.C., Montecucco C. Botulinum neurotoxins serotype A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 1993, 335:99-103.
73. Schiavo G., Malizio C., Trimble W.S., Polverino de Laureto P., Milan G., Sugiyama H., Johnson E.A., Montecucco C. Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala/Ala peptide bond. J. Biol. Chem. 1994, 269:20213-20216.
74. Schiavo G., Shone C.C., Bennett M.K., Scheller R.H., Montecucco C. Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins. J. Biol. Chem. 1995, 270:10566-10570.
75. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80:1-50.
76. Scott A.B. Clostridial toxin as therapeutic agents. Botulinum Neurotoxin and Tetanus Toxin 1989, 399-412. Academic Press, New York. L.L. Simpson (Ed.).
77. Sellin L.C. Botulinum toxin and the blockade of transmitter release. Asia Pac. J. Pharmacol. 1987, 2:203-222.
78. Shone C.C., Tranter H.S. Growth of clostridia and preparation of their Neurotoxins. Curr. Top. Microbiol. Immunol. 1995, 195:143-160.
79. Simpson L.L., Coffield J.A., Bakry N. Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins. J. Pharmacol. Exp. Ther. 1994, 269:256-262.
80. Smith L.A. Botulism and vaccines for its prevention. Vaccine 2009, 27(Suppl. 4):D33-D39.
81. Strotmeier J., Lee K., Völker A.K., Mahrhold S., Zong Y., Zeiser J., Zhou J., Pich A., Bigalke H., Binz T., Rummel A., Jin R. Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner. Biochem. J. 2010, 431:207-216.
82. Swaminathan S. Molecular structures and functional relationships in clostridial neurotoxins. FEBS J. 2011, 278:4467-4485.
83. Swaminathan S., Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 2000, 7:693-699.
84. Tonello F., Montecucco C. The anthrax lethal factor and its MAPK kinase-specific metalloprotease activity. Mol. Aspects Med. 2009, 30:431-438.
85. Truong D.D., Jost W.H. Botulinum toxin: clinical use. Parkinsonism Relat. Disord. 2006, 12:331-355.
86. Vaidyanathan V.V., Yoshino K., Jahnz M., Dörries C., Bade S., Nauenburg S., Niemann H., Binz T. Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme-substrate complexes and cleavage. J. Neurochem. 1999, 72:327-337.
87. van Ermengen E. über ein neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Z. Hyg. Infektkr. 1897, 26:1-56.
88. Verderio C., Grumelli C., Raiteri L., Coco S., Paluzzi S., Caccin P., Rossetto O., Bonanno G., Montecucco C., Matteoli M. Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 2007, 8:142-153.
89. Willison H.J., Almemar A., Veitch J., Thrush D. Acute ataxic neuropathy with cross-reactive antibodies to GD1b and GD3 gangliosides. Neurology 1994, 44:2395-2397.
90. Witcome M., Rossetto O., Montecucco C., Shone C.C. Substrate residues N-terminal to the cleavage site of botulinum type B neurotoxin play a role in determining the specificity of its endopeptidase activity. FEBS Lett. 1996, 386:133-136.
91. Wobeser G. Avian botulism - another perspective. J. Wildl. Dis. 1997, 33:181-186.
92. Yamasaki S., Hu Y., Binz T., Kalkuhl A., Kurazono H., Tamura T., Jahn R., Kandel E., Niemann H. Synaptobrevin/VAMP of Aplysia californica: structure and proteolysis by tetanus and botulinal neurotoxins type D and F. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:4688-4692.
93. Yamasaki S., Baumeister A., Binz T., Blasi J., Link E., Cornille F., Roques B., Fykse E.M., Südhof T.C., Jahn R., Niemann H. Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J. Biol. Chem. 1994, 269:12764-12772.